Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pemphigus Vulgaris - Overview
Pemphigus Vulgaris - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pemphigus Vulgaris - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pemphigus Vulgaris - Companies Involved in Therapeutics Development
Argenx SE
BioXpress Therapeutics SA
Cabaletta Bio Inc
Daewoong Pharmaceutical Co Ltd
Evopoint Bioscience Co Ltd
Hall Biopharma Co Ltd
iBio Inc
ImmunoWork LLC
Octagon Therapeutics Inc
Pharmapraxis
Serpin Pharma LLC
Topas Therapeutics GmbH
Pemphigus Vulgaris - Drug Profiles
batoclimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile
Product Description
Mechanism Of Action
DSG3-CAART - Drug Profile
Product Description
Mechanism Of Action
History of Events
DSG3/1-CAART - Drug Profile
Product Description
Mechanism Of Action
History of Events
DWP-212525 - Drug Profile
Product Description
Mechanism Of Action
efgartigimod alfa - Drug Profile
Product Description
Mechanism Of Action
History of Events
OW-177 - Drug Profile
Product Description
Mechanism Of Action
Pemphigus Vulgaris - Drug Profile
Product Description
Mechanism Of Action
rituximab biobetter - Drug Profile
Product Description
Mechanism Of Action
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
SP-16 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TPM-203 - Drug Profile
Product Description
Mechanism Of Action
History of Events
XNW-1011 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Pemphigus Vulgaris - Dormant Projects
Pemphigus Vulgaris - Discontinued Products
Pemphigus Vulgaris - Product Development Milestones
Featured News & Press Releases
Sep 10, 2022: Cabaletta Bio presents new interim data from the DesCAARTes Phase 1 Trial at the 31st EADV Congress
Sep 10, 2022: Cabaletta Bio to present data at the 31st EADV Congress and provides update on DesCAARTes trial
May 18, 2022: Cabaletta Bio presents updated interim DesCAARTes trial phase 1 data at the ASGCT 25th Annual Meeting
May 02, 2022: Cabaletta Bio to present DSG3-CAART clinical data at Upcoming Scientific Meetings in May
Dec 14, 2021: Cabaletta Bio reports top-line biologic activity data from two lowest dose cohorts in DesCAARTes trial in patients with mucosal pemphigus vulgaris
Nov 15, 2021: Zai Lab announces first patient dosed in Greater Chi in global registratiol clinical trial of efgartigimod in pemphigus
Nov 01, 2021: Cabaletta Bio reports clinical data from the third dose cohort in DesCAARTes trial in patients with mPV
Aug 18, 2021: Cabaletta Bio reports clinical data from the second dose cohort in DesCAARTes trial in patients with mPV
May 03, 2021: Cabaletta Bio reports acute safety data from the first dose cohort in DesCAARTes trial
Dec 08, 2020: Cabaletta Bio announces first patient dosed in Landmark DesCAARTes trial of DSG3-CAART for treatment of mucosal-domint pemphigus vulgaris
Aug 25, 2020: Cabaletta Bio announces publication of comprehensive preclinical study results for DSG3-CAART in pemphigus vulgaris
May 06, 2020: Cabaletta Bio receives FDA Fast Track Desigtion for DSG3-CAART for the treatment of Mucosal Pemphigus Vulgaris
Jan 29, 2020: FDA grants DSG3-CAART orphan drug desigtion for the treatment of pemphigus vulgaris
Dec 18, 2019: Topas Therapeutics announces first patient enrolled in phase 1 trial with TPM203 in pemphigus vulgaris
Oct 01, 2019: Cabaletta Bio receives IND clearance from FDA to initiate first clinical trial of DSG3-CAART in patients with Mucosal Pemphigus Vulgaris
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Pemphigus Vulgaris, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Pemphigus Vulgaris, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pemphigus Vulgaris - Pipeline by Argenx SE, 2022
Pemphigus Vulgaris - Pipeline by BioXpress Therapeutics SA, 2022
Pemphigus Vulgaris - Pipeline by Cabaletta Bio Inc, 2022
Pemphigus Vulgaris - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Pemphigus Vulgaris - Pipeline by Evopoint Bioscience Co Ltd, 2022
Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co Ltd, 2022
Pemphigus Vulgaris - Pipeline by iBio Inc, 2022
Pemphigus Vulgaris - Pipeline by ImmunoWork LLC, 2022
Pemphigus Vulgaris - Pipeline by Octagon Therapeutics Inc, 2022
Pemphigus Vulgaris - Pipeline by Pharmapraxis, 2022
Pemphigus Vulgaris - Pipeline by Serpin Pharma LLC, 2022
Pemphigus Vulgaris - Pipeline by Topas Therapeutics GmbH, 2022
Pemphigus Vulgaris - Dormant Projects, 2022
Pemphigus Vulgaris - Discontinued Products, 2022